A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:
\- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?
Participants will:
* Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks
* Visit the clinic every two to four weeks for checkups and tests
* Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib